Clinical trials
Immunization clinical trials
Below are recruiting immunization clinical trials, each written for real people, not researchers. We’re tracking 975 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06107582Recruiting
Long-term study of children with immune thrombocytopenia
This study follows children aged 6-17 with immune thrombocytopenia (ITP) over time to better understand the condition and how it changes. It aims to learn more about ITP in children to improve future care.
TianjinAges 6–17 - NCT06037811RecruitingPhase 2
Adalimumab for Immunotherapy-Related Arthritis
This study tests if a medicine called adalimumab (a type of TNF blocker) can help with new joint pain and swelling (inflammatory arthritis) caused by some immunotherapy drugs. It aims to reduce the need for high-dose steroids and improve symptoms.
London, OntarioAges 18 years+ - NCT05941741RecruitingPhase 3
Tested low-dose radiation plus cadonilimab for nasopharyngeal cancer
This Phase 3 trial studies whether adding low-dose radiation to cadonilimab (an immune therapy) can improve outcomes for people newly diagnosed with a specific type and stage of nasopharyngeal cancer. If you’re eligible, it may offer a new treatment approach and helps researchers confirm whether it works best.
Guangzhou, GuangdongAges 18–70 - NCT05799898Recruiting
Fast heart and vessel check for people on immune cancer drugs
This trial looks at a faster heart and blood-vessel assessment for people who are taking immune cancer drugs and have been referred because they might be having a heart-related side effect. It may help by speeding up evaluation and treatment decisions when symptoms raise concern.
ParisAges 18 years+ - NCT05774093Recruiting
Study how COVID immunity affects reinfection risk
This study looks at how well COVID-19 protection (immune barrier) holds up over time and how likely people are to get reinfected. It may help researchers understand who is more at risk after prior infection and why.
Guangzhou, GuangdongAges Any age - NCT05726396RecruitingPhase 2
Microbiome therapy for steroid-resistant immune colitis
This Phase 2 pilot study tests a “restorative microbiota therapy” (RMT) to treat colitis caused by immune checkpoint inhibitors when standard treatments like steroids are not working. It aims to see if this approach is safe and practical, and may improve diarrhea and gut inflammation.
Brainerd, MinnesotaAges 18 years+ - NCT05708755RecruitingPhase 2
Monitoring immune response to CMV after lung transplant
This Phase 2 study monitors how your immune system reacts to CMV (a common virus) after a lung transplant. It may help doctors understand which patients are better protected and could guide future treatments to reduce CMV-related complications.
New York, New YorkAges 18–99 - NCT05672927RecruitingPhase 4
Comparing HPV vaccine schedules: 2 doses vs 3 doses
This study compares how well your immune system responds to an HPV vaccine given as either 2 doses or 3 doses in people ages 27–45 who have never had the HPV vaccine. It may help improve HPV prevention strategies and guide the best dose schedule for adults.
Galveston, TexasAges 27–45 - NCT05648136Recruiting
Blood test study for immune markers in miscarriage and IVF failure
This study looks at immune-related blood patterns and other measurements to better understand why some women have repeated pregnancy loss or repeated IVF implantation failure. If you qualify, your answers and test results may help researchers identify biomarkers that could guide future care.
Amiens, PicardieAges 18–39 - NCT05643092Recruiting
Testing scans and biomarkers for CAR T neurotoxicity risk
This study uses blood tests and brain imaging to better understand and predict nerve-system side effects that can happen after CAR T-cell treatment. It may help doctors spot people at higher risk sooner and guide safer care.
Shijiazhuang, HebeiAges 18–80 - NCT05599880RecruitingPhase 2
Bortezomib for adults with hard-to-treat immune low platelets
This Phase 2 trial tests whether bortezomib can safely increase platelet counts in adults with immune thrombocytopenia (ITP) that keeps coming back or doesn’t respond to standard treatments. It’s for people with very low platelets who still need treatment despite prior medicines.
Guri-siAges 19 years+ - NCT05584631RecruitingPhase 1
Switching IVIG to weekly SCIG for CIDP treatment
This Phase 1 study compares IVIG given through an IV versus SCIG given under the skin, for people with CIDP. It aims to find the right weekly SCIG dose based on your current IVIG dose, which could make treatment more convenient.
New Brunswick, New JerseyAges 18–65 - NCT05584488Recruiting
Study of immune and allergy patterns over time
This study follows people with suspected or known inherited immune/allergy problems by collecting health information and blood. It may help researchers understand how immune systems and allergies behave over time and support future studies.
New York, New YorkAges Up to 99 years - NCT05528796Enrolling by invitation
Finding causes of non-immune fluid buildup in babies
This study looks for the underlying cause of “non-immune hydrops fetalis,” a serious condition where a baby has abnormal fluid buildup. It focuses on families whose usual genetic tests didn’t find an answer (or weren’t completed before birth).
San Francisco, CaliforniaAges 18–60 - NCT05377307Recruiting
Long-term follow-up for gene-edited immune cell therapy
This study checks how people are doing years after receiving a specific company’s gene-edited immune cell treatment. It helps researchers learn about long-term safety and health outcomes.
Kaohsiung, TaiwanAges Any age - NCT03369821Recruiting
Study of immune changes in very early childhood type 1 diabetes
This study looks at immune system cells and gene activity in infants and young children to understand what causes type 1 diabetes to start so early. It may help researchers find earlier warning signs and better ways to support families right at diagnosis.
Seattle, WashingtonAges Up to 70 years - NCT05345847Recruiting
Steroid-sparing treatment for immune hepatitis during cancer immunotherapy
This trial studies a way to treat inflammation of the liver (hepatitis) caused by immune cancer medicines (anti-PD-1/PD-L1, sometimes with anti-CTLA-4) without relying on high-dose steroids. It may help reduce steroid side effects while keeping liver inflammation under control.
Calgary, AlbertaAges 18 years+ - NCT05318196Recruiting
Predict kidney disease risk and progression from patient data
This trial looks at ways to predict how kidney disease may develop, change, or cause complications using information from patients. It may help doctors identify people at higher risk and tailor care earlier.
ToulouseAges 18–99 - NCT05338190RecruitingPhase 3
Belimumab added to rituximab for chronic immune thrombocytopenia
This Phase 3 study tests whether adding an injection called belimumab (or a placebo) to rituximab works better and is safe for adults with long-lasting immune thrombocytopenia (ITP). You may be eligible if your platelet counts stay low despite prior steroid and/or IVIG treatment and if infections, vaccines, and other health conditions meet the study rules.
CréteilAges 18 years+ - NCT05354765Recruiting
Collect immune cells by lymphapheresis to study cancer response
This trial studies how changing your immune system (with earlier treatments) affects cancer by collecting immune cells from your blood using a process called lymphapheresis. It may help researchers find better ways to monitor immune-related responses and side effects.
ParisAges 18 years+ - NCT05306925Recruiting
Arginine supplement study for newborns after major gut surgery
This study looks at whether giving an amino-acid supplement called arginine to newborns after major bowel surgery can improve the baby’s immune response. It may help doctors understand how to support recovery after conditions like necrotizing enterocolitis or certain birth defects.
Liverpool, MerseysideAges 5 months–10 months - NCT05277129Recruiting
Study of the immune response soon after stroke
This study looks at how your body’s immune system reacts in the first hours after a stroke. It may help researchers understand stroke-related immune changes and improve future treatments.
LørenskogAges 18 years+ - NCT05139706Recruiting
Study immune side effects after cancer immunotherapy
This study looks at how immune-related side effects happen in people treated with certain cancer immunotherapies. It also includes some healthy volunteers and people who already have similar autoimmune conditions, to better understand and compare these reactions.
Montreal, QuebecAges 18–100 - NCT05070845RecruitingPhase 2
Study drug for immune thrombocytopenia with low platelets
This Phase 2 study tests how safe and effective PF-06835375 is for people with primary immune thrombocytopenia (ITP), a condition where platelet counts are too low. It may help reduce bleeding risk by improving platelet levels, depending on the results.
Greenville, North CarolinaAges 18–70
Hear when a new Immunization trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for immunization?
- Yes. Clin2 currently lists 975 recruiting immunization studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a immunization trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a immunization trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.